Luminex® and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion

Transfusion Medicine and Hemotherapy

Volumn 40, Issue 3, 2013, Pages 182-189

  Lachmann, Nils ^a   Todorova, Kremena ^a   Schulze, Harald ^a   Schönemann, Constanze ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

HLA antibodies; Luminex; Transfusion

Indexed keywords

HLA ANTIBODY;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; GRAFT FAILURE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; LUNG INJURY; ORGAN TRANSPLANTATION; PLASMA TRANSFUSION; REFRACTORY THROMBOCYTOPENIA; REVIEW; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; THROMBOCYTE TRANSFUSION;

EID: 84879371495     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000351459     Document Type: Review

References (67)

1. Dausset J: Iso-leuko-antibodies [in French). Acta Haematol 1958;20:156-166.
2. Van Rood JJ, Eernisse JG, Van Leeuwen A: Leucocyte antibodies in sera from pregnant women. Nature 1958;181:1735-1736.
3. Thorsby E: A short history of HLA. Tissue Antigens 2009;74:101-116.
4. Dausset J, Rapaport FT, Colombani J, Feingold N: A leucocyte group and its relationship to tissue histocompatibility in man. Transplantation 1965;3:701-705.
5. Worthington JE, Robson AJ, Sheldon S, Langton A, Martin S: A comparison of enzyme-linked immuno-absorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001;62:1178-1184.
6. Zachary AA, Vega RM, Lucas DP, Leffell MS: HLA antibody detection and characterization by solid phase immunoassays: Methods and pitfalls. Meth Mol Biol 2012;882:289-308.
7. Altermann WW, Seliger B, Sei S, Wendt D, Schlaf G: Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol Histopathol 2006;21: 1115-1124.
8. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis, II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanaku-mar T, Suciu-Foca N, Sumitran-Holgersson S, Tan-abe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G: Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95:19-47.
9. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M: The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007;7: 1027-1031.
10. Vaidya S: Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008;85:1046-1050.
11. Schönemann C: Management falsch positiver XMAP-Antikörperbefunde bei der Bestimmung von HLA-Antikörpern. Transfusionsmedizin 2012;2:192-196.
12. Butch AW: Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem 2000;46: 1719-1721.
13. Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ: Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation 2009;87:813-820.
14. Zachary AA, Lucas DP, Detrick B, Leffell MS: Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009;70:496-501.
15. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D: HLA antibody specification using single-antigen beads - a technical solution for the prozone effect. Transplantation 2011;92:510-515.
16. Kosmoliaptsis V, O'Rourke C, Bradley JA, Taylor CJ: Improved Luminex-based human leukocyte antigen-specific antibody screening using dithiothrei-tol-treated sera. Hum Immunol 2010;71:45-49.
17. Weinstock C, Schnaidt M: The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 2012;doi: 10.1111/J.1744-313X.2012.01147.x.
18. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee J-H, El-Awar N, Alberü J: 'Natural human leukocyte antigen antibodies found in nonal-loimmunized healthy males. Transplantation 2008; 86:1111-1115.
19. El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, Maruya E, Poli F: Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009;70:844-853.
20. McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P: Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med 1995;181:2085-2095.
21. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA: Back to the future: Application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009;70:563-568.
22. Arnold ML, Heinemann FM, Horn P, Ziemann M, Lachmann N, Muhlbacher A, Dick A, Ender A, Tham-manichanond D, Fischer GF, Schaub S, Hallensleben M, Mytilineos J, Hitzler WE, Seidl C, Doxiadis, II, Spriewald BM: 16[th) IHIW: Anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates. Int J Immunogenet 2013;40:17-20.
23. Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P: Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011;92:41-47.
24. Tyan DB: New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant 2012;17:409-415.
25. Wahrmann M, Exner M, Haidbauer B, Schillinger M, Regele H, Kormoczi G, Bohmig GA: [C4d]FlowPRA screening - a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 2005;66:526-534.
26. Smith JD, Hamour IM, Banner NR, Rose ML: C4d fixing, Luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007;7:2809-2815.
27. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, Rosenthal D, Reinhartz O, Tyan D: Clinical usefulness of a novel Clq assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011;30:158-163.
28. Lachmann N, Todorova K, Schulze H, Schonemann C: Systematic comparison of four cell- and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 2013;95: 694-700.
29. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739.
30. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
31. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4: 378-383.
32. Sellares J, Freitas DGd, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF: Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012;12: 388-399.
33. Terasaki PI: Humoral theory of transplantation. Am J Transplant 2003;3:665-673.
34. Wahrmann M, Bartel G, Exner M, Regele H, Körmöczi GF, Fischer GF, Böhmig GA: Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transplant Int 2009;22:982-989.
35. Otten HG, Verhaar MC, Borst HPE, Hene RJ, van Zuilen AD: Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12:1618-1623.
36. Gillespie A, Lee IJ: Biomarkers in renal transplantation. Biomark Med 2008;2:603-612.
37. Liefeldt L, Brakemeier S, Glander P, Waiser J, Lachmann N, Schönemann C, Zukunft B, Illigens P, Schmidt D, Wu K, Rudolph B, Neumayer H-H, Budde K: Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012;12:1192-1198.
38. Waiser J, Budde K, Schütz M, Liefeldt L, Rudolph B, Schönemann C, Neumayer H-H, Lachmann N: Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant 2012;27:1246-1251.
39. Brand A, Doxiadis IN, Roelen DL: On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens 2013;81:1-11.
40. Storb R, Prentice RL, Thomas ED: Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival. J Clin Invest 1977;59:625-632.
41. Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M, Frangoul H, Gupta V, Hale GA, Hurley CK, Marino S, Oudshoorn M, Reddy V, Shaw P, Lee SJ, Woolfrey A: Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for non-malignant disorders. Blood 2012;120:2918-2924.
42. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernan-dez-Vina M: High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009;88: 1019-1024.
43. Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, Fujioka T, Tamaki H, Ikegame K, Okada M, Soma T, Hayashi K, Fujii N, Onuma T, Kusunoki Y, Saji H, Ogawa H: Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012;47:508-515.
44. Taniguchi K, Yoshihara S, Maruya E, Ikegame K, Kaida K, Hayashi K, Kato R, Inoue T, Fujioka T, Tamaki H, Okada M, Onuma T, Fujii N, Kusunoki Y, Soma T, Saji H, Ogawa H: Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors. Bone Marrow Transplant 2012;47:1338-1342.
45. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
46. Magee BA, Martin J, Cole MP, Morris KG, Courtney AE: Effects of HLA-matched blood transfusion for patients awaiting renal transplantation. Transplantation 2012;94:1111-1116.
47. Rivera R, Scornik JC: HLA antigens on red cells. Implications for achieving low HLA antigen content in blood transfusions. Transfusion 1986;26:375-381.
48. de Villartay JP, Rouger P, Muller JY, Salmon C: HLA antigens on peripheral red blood cells: analysis by flow cytofluorometry using monoclonal antibodies. Tissue Antigens 1985;26:12-19.
49. Scornik JC, Meier-Kriesche HU: Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011;11:1785-1791.
50. Obrador GT, Macdougall IC: Effect of red cell transfusions on future kidney transplantation. Clin J Am Soc Nephrol 2012;doi: 10.2215/CJN.00020112.
51. Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Brand A: Effects of allogeneic leukocytes in blood transfusions during cardiac surgery on inflammatory mediators and postoperative complications. Crit Care Med 2010;38:546-552.
52. Hyun J, Park KD, Yoo Y, Lee B, Han BY, Song EY, Park MH: Effects of different sensitization events on HLA alloimmunization in solid organ transplantation patients. Transplant Proc 2012;44:222-225.
53. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200-205.
54. Kekomaki R: Use of HLA- and HPA-matched platelets in alloimmunized patients. Vox Sang 1998;74 [suppl2):359-363.
55. Hod E, Schwartz J: Platelet transfusion refractoriness. Br J Haematol 2008;142:348-360.
56. Fontaine MJ, Kuo J, Chen G, Galel SA, Miller E, Seque-ira F, Viele M, Goodnough LT, Tyan DB: Complement [Clq) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011;51:2611-2618.
57. Wiita AP, Nambiar A: Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes [CME). Transfusion 2012;52: 2146-2154.
58. Bux J: Transfusion-related acute lung injury [TRALI): a serious adverse event of blood transfusion. Vox Sang 2005;89:1-10.
59. Flesch BK, Petershofen EK, Bux J: TRALI - new challenges for histocompatibility and immunogenetics in transfusion medicine. Tissue Antigens 2011;78:1-7.
60. Fontaine MJ, Malone J, Mullins FM, Grumet FC: Diagnosis of transfusion-related acute lung injury: TRALI or not TRALI? Ann Clin Lab Sei 2006;36:53-58.
61. Vlaar AP, Hofstra JJ, Determann RM, Veelo DP, Paulus F, Kulik W, Korevaar J, de Mol BA, Koopman MM, Porcelijn L, Binnekade JM, Vroom MB, Schultz MJ, Juf-fermans NP: The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: A prospective nested case-control study. Blood 2011;117:4218-4225.
62. Imoto S, Kawamura K, Tokumine Y, Araki N, Akita S, Nishimura C, Inaba H, Saigo K, Mabuchi O, Okazaki H: Acute non-hemolytic transfusion reactions and HLA class I antibody: advantages of solid phase assay compared with conventional complement-dependent assay. Transfus Med 2010;20:95-103.
63. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA, Panel TC: Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005;19:2-31.
64. Lucas G, Win N, Calvert A, Green A, Griffin E, Ben-dukidze N, Hopkins M, Browne T, Poles A, Chapman C, Massey E: Reducing the incidence of TRALI in the UK: the results of screening for donor leucocyte antibodies and the development of national guidelines. Vox Sang 2012;103:10-17.
65. Muller MC, Porcelijn L, Vlaar AP: Prevention of immune-mediated trans fusion-related acute lung injury; from bloodbank to patient. Curr Pharm Des 2012;18:3241-3248.
66. Lin Y, Saw CL, Hannach B, Goldman M: Transfusion-related acute lung injury prevention measures and their impact at Canadian blood services. Transfusion 2012;52:567-574.
67. Maiers M, Gragert L, Klitz W: High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007;68:779-788.